The role of caveolin-1 in prostate cancer: Clinical implications

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 1, 2010, Pages 6-11

  Thompson, T C ^a   Tahir, S A ^a   Li, L ^a   Watanabe, M ^b   Naruishi, K ^b   Yang, G ^a   Kadmon, D ^c   Logothetis, C J ^a   Troncoso, P ^a   Ren, C ^a   Goltsov, A ^a   Park, S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Biomarkers; Caveolin 1; Progression

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CAVEOLIN 1; ONCOPROTEIN; PROTEIN KINASE B; TUMOR MARKER;

AUTOCRINE EFFECT; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GENETICS; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CARCINOGENESIS; CELL STIMULATION; CELL SURVIVAL; DIGITAL RECTAL EXAMINATION; DISEASE ACTIVITY; DISEASE COURSE; DRUG TARGETING; ENZYME ACTIVATION; GENE FUNCTION; GENETIC TRANSCRIPTION; HETEROZYGOSITY; HUMAN; METASTASIS; NONHUMAN; ONCOGENE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TARGETING; REFERENCE VALUE; REVIEW; TUMOR VASCULARIZATION; UPREGULATION;

CAVEOLIN 1; DISEASE PROGRESSION; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 76949095336     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.29     Document Type: Review

References (66)

1. Shaul PW, Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol 1998; 275: L843-L851.
2. Sternberg PW, Schmid SL. Caveolin, cholesterol and Ras signalling. Nat Cell Biol 1999; 1: E35-E37.
3. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol 2005; 288: C494-C506.
4. Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 2005; 118: 1493-1503.
5. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 2001; 61: 4386-4392.
6. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J et al. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 2008; 68: 731-739.
7. Williams TM, Hassan GS, Li J, Cohen AW, Medina FA, Philippe GF et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in TRAMP mice. J Biol Chem 2005; 10: 1074.
8. Woodman SE, Ashton AW, Schubert W, Lee H, Williams TM, Medina FA et al. Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. Am J Pathol 2003; 162: 2059-2068.
9. Shatz M, Liscovitch M. Caveolin-1: a tumor-promoting role in human cancer. Int J Radiat Biol 2008; 84: 177-189.
10. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998; 4: 1873-1880.
11. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 1999; 59: 5719-5723.
12. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM. Upregulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 2002; 161: 1647-1656.
13. Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int 2004; 93: 291-296.
14. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002; 94: 929-933.
15. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61: 3882-3885.
16. Wu D, Foreman TL, Gregory CW, McJilton MA, Wescot GG, Ford OH et al. Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res 2002; 62: 2423-2429.
17. Bartz R, Zhou J, Hsieh JT, Ying Y, Li W, Liu P. Caveolin-1 secreting LNCaP cells induce tumor growth of caveolin-1 negative LNCaP cells in vivo. Int J Cancer 2008; 122: 520-525.
18. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003; 23: 9389-9404.
19. Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD et al. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 2003; 9: 3653-3659.
20. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP et al. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 2006; 12: 4872-4875.
21. Goto T, Nguyen BP, Nakano M, Ehara H, Yamamoto N, Deguchi T. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population. Urology 2008; 72: 167-171.
22. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 2007; 67: 614-622.
23. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84: 1341-1379.
24. Engelman JA, Zhang XL, Lisanti MP. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 1998; 436: 403-410.
25. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998; 153: 141-148.
26. Bachmann N, Haeusler J, Luedeke M, Kuefer R, Perner S, Assun G et al. Expression changes of CAV1 and EZH2, located on 7q31 approximately q36, are rarely related to genomic alterations in primary prostate carcinoma. Cancer Genet Cytogenet 2008; 182: 103-110.
27. Hurlstone AF, Reid G, Reeves JR, Fraser J, Strathdee G, Rahilly M et al. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 1999; 18: 1881-1890.
28. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, Brothman AR. Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 2001; 46: 249-256.
29. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M et al. miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009; 69: 2287-2295.
30. Thompson TC, Park SH, Timme TL, Ren C, EasthamJA, Donehower LA et al. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 1995; 10: 869-879.
31. Dall'era MA, Cooperberg MR, Chang JM, Davies BJ, Albertsen PC, Klotz LH et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008; 112: 1650-1659.
32. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells [see comments]. Nat Med 1998; 4: 1062-1064.
33. Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 2001; 276: 13442-13451.
34. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER. Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol 2003; 23: 1633-1646.
35. Patlolla JM, Swamy MV, Raju J, Rao CV. Overexpression of caveolin-1 in experimental colon adenocarcinomas and human colon cancer cell lines. Oncol Rep 2004; 11: 957-963.
36. Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, Mellon JK. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 2001; 58: 811-814.
37. Suzuoki M,Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002; 87: 1140-1144.
38. Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M et al. Caveolin-1 expression in ovarian carcinoma is MDR1 independent. Am J Clin Pathol 2002; 117: 225-234.
39. Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, Van Dam P et al. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 2006; 95: 219-228.
40. Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS et al. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 2003; 42: 195-202.
41. Zhang X, Ling MT, Wang Q, Lau CK, Leung SC, Lee TK et al. Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. J Biol Chem 2007; 282: 33284-33294.
42. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005; 8: 108-118. (Pubitemid 43118073)
43. Di Vizio D, Adam RM, Kim J, Kim R, Sotgia F, Williams T et al. Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle 2008; 7: 2257-2267.
44. Glenney Jr JR, Zokas L. Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol 1989; 108: 2401-2408.
45. Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, Griffith OL et al. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res 2008; 68: 8210-8220.
46. Ayala GE, Dai H, Tahir SA, Li R, Timme T, Ittmann M et al. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res 2006; 66: 5159-5164.
47. Liu P, Li WP, Machleidt T, Anderson RG. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nat Cell Biol 1999; 1: 369-375.
48. Llorente A, de Marco MC, Alonso MA. Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line. J Cell Sci 2004; 117: 5343-5351.
49. Lu Q, Zhang J, Allison R, Gay H, Yang WX, Bhowmick NA et al. Identification of extracellular delta-catenin accumulation for prostate cancer detection. Prostate 2009; 69: 411-418.
50. Chung LW, Huang WC, Sung SY, Wu D, Odero-Marah V, Nomura T et al. Stromal-epithelial interaction in prostate cancer progression. Clin Genitourin Cancer 2006; 5: 162-170.
51. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004; 11: 709-724.
52. Morrissey C, Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 2007; 101: 873-886.
53. Reynolds AR, Kyprianou N. Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol 2006; 147 (Suppl 2): S144-S152.
54. Josko J, Mazurek M. Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 2004; 10: RA89-RA98.
55. Cash J, Korchnak A, Gorman J, Tandon Y, Fraizer G. VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells. Oncol Rep 2007; 17: 1413-1419.
56. Kanies CL, Smith JJ, Kis C, Schmidt C, Levy S, Khabar KS et al. Oncogenic Ras and transforming growth factor-beta synergistically regulate AU-rich element-containing mRNAs during epithelial to mesenchymal transition. Mol Cancer Res 2008; 6: 1124-1136.
57. Song QH, Klepeis VE, Nugent MA, Trinkaus-Randall V. TGF-beta1 regulates TGF-beta1 and FGF-2 mRNA expression during fibroblast wound healing. Mol Pathol 2002; 55: 164-176.
58. Touriol C, Morillon A, Gensac MC, Prats H, Prats AC. Expression of human fibroblast growth factor 2 mRNA is posttranscriptionally controlled by a unique destabilizing element present in the 30-untranslated region between alternative polyadenylation sites. J Biol Chem 1999; 274: 21402-21408.
59. Yang G, Addai J, Wheeler TM, Frolov A, Miles BJ, Kadmon D et al. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol 2007; 38: 1688-1695.
60. Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E et al. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther 2006; 13: 716-728.
61. Efstathiou E, Troncoso P,Wen S, Do KA, Pettaway CA, Pisters LL et al. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 2007; 13: 1224-1231.
62. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG et al. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 2004; 10: 2587-2593.
63. Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE et al. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer 2007; 110: 2628-2639.
64. Watanabe M, Yang G, Cao G, Tahir SA, Naruishi K, Tabata K et al. Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Can Res 2009 (in press).
65. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009; 59: 111-137.
66. Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007; 39: 271-278.